Impact of graft‐versus‐host disease and graft‐versus‐leukemia effect based on minimal residual disease in Philadelphia chromosome‐positive acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Impact of graft‐versus‐host disease and graft‐versus‐leukemia effect based on minimal residual disease in Philadelphia chromosome‐positive acute lymphoblastic leukemia

Published:2020-03-02 Issue:1 Volume:190 Page:84-92
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Akahoshi Yu¹^ORCID,Igarashi Aiko²,Fukuda Takahiro³,Uchida Naoyuki⁴,Tanaka Masatsugu⁵,Ozawa Yukiyasu⁶,Kanda Yoshinobu¹⁷,Onizuka Makoto⁸,Ichinohe Tatsuo⁹,Tanaka Junji¹⁰,Atsuta Yoshiko¹¹¹²^ORCID,Kako Shinichi¹^ORCID,

Affiliation:

1. Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan

2. Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

3. Division of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan

4. Department of Hematology Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital Tokyo Japan

5. Department of Hematology Kanagawa Cancer Center Yokohama Japan

6. Department of Hematology Japanese Red Cross Nagoya First Hospital Nagoya Japan

7. Division of Hematology Department of Medicine Jichi Medical University Tochigi Japan

8. Department of Hematology and Oncology Tokai University School of Medicine Kanagawa Japan

9. Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan

10. Department of Hematology Tokyo Women's Medical University Tokyo Japan

11. Japanese Data Center for Hematopoietic Cell Transplantation Nagoya Japan

12. Department of Healthcare Administration Nagoya University Graduate School of Medicine Nagoya Japan

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16540

Reference33 articles.

1. Additional Cytogenetic Abnormalities with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era

2. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia

3. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)

4. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation

5. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD;Blood;2024-08-29

2. Selection of statistical tests considering competing risks: the importance of understanding the assumptions in each test;Blood Advances;2024-05-28

3. Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission;Cancer Medicine;2024-01

4. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD;Blood Advances;2023-08-11

5. Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph⁺ALL: A retrospective nationwide study;American Journal of Hematology;2023-07-26